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Introduction {#ehf212525-sec-0004}
============

Heart failure (HF) is a serious and progressive cardiac illness that adversely affects quality of life, increases healthcare costs substantially, and is a major cause of mortality.[1](#ehf212525-bib-0001){ref-type="ref"}, [2](#ehf212525-bib-0002){ref-type="ref"}, [3](#ehf212525-bib-0003){ref-type="ref"} It affects about 26 million people worldwide,[4](#ehf212525-bib-0004){ref-type="ref"} and the annual global cost burden was estimated at \$108bn in 2012, which is projected to increase by 127% by 2030. The prevalence estimates are said to increase by 46% in the USA with characteristic dip in age at occurrence.[5](#ehf212525-bib-0005){ref-type="ref"} The global public health burden of HF is enormous accounting for high rates of prevalence in European and Southeast Asian population ranging from 1% to 6.7% respectively with varying disparities in clinical characteristics due to geographical variations. However, owing to longevity in human lifespan, HF has been further projected to rise in population aged \>64 years. These temporal trends are a cause of concern and demand urgent control measures based on etiological factors and prognostic outcomes of HF.[6](#ehf212525-bib-0006){ref-type="ref"} Technological advancements in imaging techniques not only have improved diagnosis but also have further facilitated survival prediction and risk stratification of HF patients.[7](#ehf212525-bib-0007){ref-type="ref"} But despite exceptional technological advances, HF is associated with high rates of disability and death, although the long‐term mortality rates have improved over time.[8](#ehf212525-bib-0008){ref-type="ref"}, [9](#ehf212525-bib-0009){ref-type="ref"}, [10](#ehf212525-bib-0010){ref-type="ref"} The in‐hospital and long‐term outcomes of HF are determined by numerous intrinsic factors and presence of co‐morbidities like obesity, diabetes, hypertension, renal health, and cardiac health by itself like compromised ejection fraction, ventricular arrhythmias being one of the major determinants associated with increased risk of short‐term and long‐term mortality.[11](#ehf212525-bib-0011){ref-type="ref"}, [12](#ehf212525-bib-0012){ref-type="ref"}, [13](#ehf212525-bib-0013){ref-type="ref"} Large international multi‐centric prospective studies like EuroHeart Failure, GRACE, and ASCEND have documented in‐hospital and long term outcomes associated with HF among multi‐ethnic population,[14](#ehf212525-bib-0014){ref-type="ref"}, [15](#ehf212525-bib-0015){ref-type="ref"}, [16](#ehf212525-bib-0016){ref-type="ref"} but literature from Middle Eastern region on the contrary is mostly limited to prevalence studies reporting rates of occurrence of cardiovascular diseases. Prospective studies describing long‐term outcomes of HF are rare, and one such study from the region of Saudi Arabia known as Saudi Project for Assessment of Coronary Events (SPACE) registry in 2012 had demonstrated risk factors and mortality due to VA in patients with acute coronary syndrome.[17](#ehf212525-bib-0017){ref-type="ref"} Although these studies focused on certain types of arrhythmias such as premature ventricular complexes (PVCs) and non‐sustained ventricular tachycardia (NSVT) and their adverse outcomes, data related to sustained ventricular tachycardia and ventricular fibrillation in HF patients are sparse in Saudi Arabia. The present study is first to document the incidence of sustained VT and VF, henceforth will be termed as ventricular arrhythmia (VA), its predictors, and associated outcomes in patients hospitalized with HF using data from HEart function Assessment Registry Trial in Saudi Arabia (HEARTS registry). HEARTS is the first national registry of HF patients linking 18 cardiac care hospitals in Saudi Arabia, registering more than 2000 patients in just 1 year, which points towards the gravity of situation in Saudi Arabia. The current study describes the impact of ventricular arrhythmia by subgroup analyses presenting the clinical picture, predictors, and mortality rates of HF patients among already developed VA/VT patients compared with those without VA. Furthermore, patient characteristics associated with an increased risk of developing ventricular arrhythmia would help to establish a baseline from which further studies can determine temporal changes in the prognosis of VA‐related HF. Evaluating these patient characteristics may help in identifying high‐risk VA patients.

Methods {#ehf212525-sec-0005}
=======

HEARTS registry is a national prospective registry involving cardiac care hospitals across the Kingdom of Saudi Arabia, forming a representative sample of Saudi population. To stay brief, the Kingdom of Saudi Arabia is the largest country in the Arabian Peninsula, and it is the second largest producer of crude oil in the world with a gross domestic product per capita of 21 057.33 USD in 2017. The study design, details of study population, definition of study variables, and procedures have been well described and published previously.[18](#ehf212525-bib-0018){ref-type="ref"}, [19](#ehf212525-bib-0019){ref-type="ref"} The registry had enrolled 2610 patients admitted into the coronary care unit/intensive care unit or the wards, with acute decompensated HF whether *de novo* (no previous history of HF) or with acute/chronic HF. Diagnosis of HF and the standard variables definitions were as per the American College of Cardiology, American Heart Association, and European Society of Cardiology definitions. HF patients with ejection fraction \<30% and persistent New York Heart Association Class III or IV formed the study population. Development of sustained ventricular tachycardia or ventricular fibrillation or both while being hospitalized for HF management was the main outcome measure. VF was identified at admission or during the process of hospitalization if the patient showed irregular undulations of the electrocardiogram consistent with the diagnosis. VT was identified by a regular wide complex tachycardia lasting \>30 s or requiring termination because of haemodynamic instability. Additionally, other in‐hospital events and short‐term and long‐term all‐cause mortality rates of the patients were also measured in the 7 year follow‐up period. Patients less than 18 years of age, those who did not wish to participate, and those who were treated and discharged from the emergency department without hospital admission were excluded from the study. A verbal informed consent was obtained from the patients or their relatives. Ethical approval of the study was obtained by each of the hospital\'s ethics committee or the institutional review board.

Statistical methods {#ehf212525-sec-0006}
-------------------

The statistical analyses were performed using SPSS version 21.0 (SPSS Inc.).Continuous variables of normally distributed data were described using mean and standard deviation (SD), while median and inter‐quartile range were used to represent skewed data. Test of significance was performed using the *t*‐test or Mann--Whitney *U* test as needed to satisfy the normality of assumptions. Categorical variables were presented as frequencies and percentages, and bivariate associations between the two groups were compared using a *Z* test for proportion. Predictors of mortality were assessed using both univariate and multivariate regression models to obtain independent predictors. Stepwise multiple regression models were applied to select independent predictors in the multivariate models. Crude and adjusted odds ratios, *P* values, and 95% confidence intervals from regression models were used to report summary statistics. Kaplan--Meier curves were used to depict the survival pattern of the patients with HF in the cohort.

Results {#ehf212525-sec-0007}
=======

Patient characteristics {#ehf212525-sec-0008}
-----------------------

The HEARTS study obtained 4.2% incidence of in‐hospital VA after 7 years of follow‐up. *Table* [1](#ehf212525-tbl-0001){ref-type="table"} shows the comparison of the prevalence of risk factors among VA and non‐VA complicated HF patients. In‐hospital VA was significantly higher among men (*P* = 0.029), and the mean age was lesser compared with the non‐VA group (*P* = 0.042). Other risk factors that appeared significant among the in‐hospital VA patients were previous history of VF/VT (*P* \< 0.001), family history of cardiomyopathy (*P* = 0.020), and smoking (*P* = 0.003). Although non‐significant, VA patients were more likely to report history of non‐ischaemic‐related chronic HF followed by history of ischaemic heart disease. Hypertension and diabetes were the two most prevalent co‐morbidities in both the groups.

###### 

Demographics, medical history, and risk factors between VA and non‐VA patients

  Variable                                          Heart failure patients                               
  ------------------------------------------------- ------------------------ ------------- ------------- ---------
  Demographics                                                                                           
  Age, mean (SD)                                    61.3 (15.0)              58.5 (16.3)   61.5 (15)     0.042
  Male gender                                       1717 (65.8)              83 (75.4)     1634 (65.3)   0.029
  Saudi nation                                      2230 (85.4)              85 (77.3)     2145 (85.8)   0.013
  Body mass index (kg/m^2^), mean (SD)              29.2 (6.7)               28.7 (5.9)    29.2 (6.8)    0.417
  Medical history                                                                                        
  Ischaemic heart disease                           1376 (52.7)              54 (49.1)     1322 (52.9)   0.369
  Congestive heart failure                          1670 (64.1)              72 (65.5)     1598 (64.0)   0.780
  Percutaneous coronary intervention                340 (13.0)               12 (10.9)     328 (13.1)    0.167
  Coronary artery bypass graft                      261 (10.0)               12 (10.9)     249 (9.9)     0.728
  Rheumatic heart disease                           183 (7.0)                7 (6.4)       176 (7.0)     0.790
  Other valvular heart disease                      390 (14.9)               21 (19.1)     369 (14.7)    0.222
  Atrial fibrillation                               408 (15.6)               12 (10.9)     396 (15.8)    0.170
  VT/VF                                             64 (2.4)                 13 (11.8)     51 (2.0)      \<0.001
  ICD                                               229 (8.7)                10 (9.0)      219 (8.7)     0.887
  CRT                                               85 (3.2)                 3 (2.7)       82 (3.3)      1.00
  CVA/TIA                                           252 (9.6)                13 (11.8)     239 (9.5)     0.418
  Peripheral arterial disease                       99 (3.8)                 2 (1.8)       97 (3.9)      0.437
  Chronic renal insufficiency                       771 (29.5)               33 (30.0)     738 (29.5)    0.935
  Anaemia                                           538 (20.6)               23 (20.9)     515 (20.6)    0.964
  Risk factors                                                                                           
  Diabetes                                          1668 (63.9)              68 (61.8)     1600 (64.0)   .698
  Hypertension                                      1831 (70.1)              71 (64.5)     1760 (70.4)   .200
  Dyslipidaemia                                     894 (34.2)               39 (35.4)     855 (34.2)    .872
  Smoking[a](#ehf212525-note-0003){ref-type="fn"}   872 (33.4)               51 (46.4)     821 (32.8)    .003
  Thyroid disease                                   172 (6.6)                5 (4.5)       167 (6.7)     .376
  Cardiotoxic chemotherapy                          23 (0.9)                 0 (0.0)       23 (0.9)      .622
  Cardiotoxic substance                             21 (0.8)                 3 (2.7)       18 (0.7)      .055
  Family history of SCD                             23 (0.9)                 2 (1.8)       21 (0.8)      .246
  Family history of CAD                             88 (3.3)                 5 (4.5)       83 (3.3)      .389
  Family history of cardiomyopathy                  26 (0.9)                 4 (3.6)       22 (0.8)      .020

CAD, coronary artery disease; CRT, cardiac resynchronization therapy; CVA/TIA, cerebrovascular accident/transient ischaemic attack; ICD, implantable cardioverter defibrillator; SCD, sudden cardiac death; SD, standard deviation; VA, ventricular arrhythmia; VT/VF, ventricular tachycardia/ventricular fibrillation.

Data are presented in *n* (%).

Including current and ex‐smokers.

*χ* ^2^ test of proportions was performed to determine the significance. A *P* value less than 0.05 was considered significant.

*Table* [2](#ehf212525-tbl-0002){ref-type="table"} illustrates the differences in clinical presentation, investigations, and procedures between the two groups. Patients with VA had significantly higher heart rate and lower systolic blood pressure and diastolic blood pressure at the time of admission (*P* \< 0.001). The most prevalent exacerbating factors for VA‐related HF were history of arrhythmia (29%; *P* \< 0.001), infections (28%, *P* = 0.04), ST elevated myocardial infarction (25.5%, *P* \< 0.001), followed by uncontrolled hypertension (10.9%, *P* = 0.017). While ischaemic heart disease (60.9%:55.5%) was the most prevalent aetiology in both VA and non‐VA HF patients; however, the differences were non‐significant. Echocardiography and coronary angiogram showed higher left ventricular systolic dysfunction (*P* = 0.002) and higher prevalence of single and triple vessel disease compared with non‐VA patients upon admission.

###### 

Differences in clinical presentation, investigations, and procedures among VA and non‐VA patients

  Variable                                                          Heart failure patients                  
  ----------------------------------------------------------------- ------------------------ -------------- ---------
  Heart rate, mean (SD)                                             95.4 (21.9)              88.5 (20.9)    \<0.001
  SBP, mean (SD)                                                    112.7 (25.8)             129.4 (31.4)   \<0.001
  DBP, mean (SD)                                                    68.1 (17.9)              74.4 (17.8)    \<0.001
  Oxygen saturation, mean (SD)                                      92.9 (7.3)               94.1 (5.9)     0.048
  Exacerbating factors                                                                                      
  STEMI                                                             28 (25.4)                248 (9.9)      \<0.001
  Uncontrolled hypertension                                         12 (10.9)                504 (20.2)     0.017
  History of arrhythmia                                             32 (29.1)                252 (10.1)     \<0.001
  Infections                                                        31 (28.2)                506 (20.2)     0.044
  Chronic obstructive pulmonary disease                             2 (1.8)                  99 (4.0)       0.442
  Worsening renal failure                                           26 (23.6)                431 (17.2)     0.084
  High‐salt diet                                                    31 (28.2)                628 (25.1)     0.471
  Medications non‐compliance                                        25 (22.7)                524 (21.0)     0.658
  Heart failure aetiology                                                                                   
  Ischaemic heart disease                                           67 (60.9)                1387 (55.5)    0.264
  Idiopathic dilated cardiomyopathy                                 21 (19.1)                410 (16.4)     0.458
  Primary valvular heart disease                                    8 (7.3)                  194 (7.7)      0.851
  Hypertensive heart disease                                        6 (5.4)                  301 (12.0)     0.036
  Investigations                                                                                            
  Sodium (mmol/L), mean (SD)                                        134.8 (6.4)              135.2 (5.3)    0.591
  Potassium (mmol/L), mean (SD)                                     4.2 (0.7)                4.3 (0.7)      0.534
  ProBNP (pg/mL), mean (SD)                                         2875 (3564)              1177 (1652)    0.099
  Positive troponin                                                 53 (48.2)                814 (32.5)     0.004
  Echocardiography                                                                                          
  LV systolic dysfunction[a](#ehf212525-note-0007){ref-type="fn"}   97 (88.2)                2056 (82.2)    0.002
  Coronary angiogram                                                                                        
  Left main vessel                                                  4 (3.6)                  24 (0.9)       0.049
  Single vessel disease                                             0 (0.0)                  105 (4.2)      0.010
  Double vessel disease                                             7 (6.3)                  109 (4.3)      0.621
  Triple vessel disease                                             19 (17.2)                236 (9.4)      0.037
  Normal angiogram                                                  12 (10.9)                171 (6.8)      0.306

DBP, diastolic blood pressure; LV, left ventricular; proBNP, pro‐brain natriuretic peptide; SBP, systolic blood pressure; SD, standard deviation; STEMI, ST elevated myocardial infarction; VA, ventricular arrhythmia.

Data are presented in *n* (%).

Ejection fraction \<40%.

*Table* [3](#ehf212525-tbl-0003){ref-type="table"} presents the results of multivariate regression analysis with in‐hospital VA as dependent variable and various co‐morbid conditions, past cardiac events, and other exacerbating factors as independent variables. ST elevated myocardial infarction, arrhythmia, hypotension (systolic blood pressure \<90 mmHg), and infection at presentation remained significant as strong predictors in the final model showing independent association with VA.

###### 

Multivariate regression analysis showing factors associated with in‐hospital ventricular arrhythmia in heart failure patients

  Associated factors         Odds ratio   95% CI      *P* value
  -------------------------- ------------ ----------- -----------
  Arrhythmia                 7            2.4--19.3   \<0.001
  STEMI                      4.7          1.6--14     0.006
  Infection                  3            1.2--7.6    0.024
  Blood pressure \<90 mmHg   3.6          1.2--11     0.023

CI, confidence interval; STEMI, ST elevated myocardial infarction.

In‐hospital ventricular arrhythmia was the dependent variable, and all other associated conditions were taken as independent variables.

The prevalence of in‐hospital events and all‐cause mortality is shown in *Table* [4](#ehf212525-tbl-0004){ref-type="table"}. Recurrent and chronic HF, haemodialysis, shock, sepsis, major bleeding, and intra‐aortic balloon pump were highly significant among the patients with VA (*P* \< 0.001). Survival analysis showed highly significant differences in all‐cause mortality for in‐hospital, 1 month, 1 year, and 3 years for VA patients compared with non‐VA (*P* \< 0.001).

###### 

Differences in in‐hospital events and mortality between VA and non‐VA patients

  Variable                    Heart failure patients                
  --------------------------- ------------------------ ------------ ---------
  In‐hospital events                                                
  Recurrent CHF               69 (62.7)                747 (29.9)   \>0.001
  Dialysis                    25 (22.7)                100 (4.0)    \>0.001
  Intra‐aortic balloon pump   28 (25.5)                58 (2.3)     \<0.001
  Sepsis                      36 (32.7)                160 (6.4)    \<0.001
  Shock                       64 (58.2)                164 (6.6)    \>0.001
  Pacing                      6 (5.4)                  30 (1.2)     0.003
  Major bleeding              10 (9.1)                 28 (1.1)     \<0.001
  ICD                         8 (7.3)                  142 (5.7)    0.483
  CRT                         5 (4.5)                  63 (2.5)     0.208
  TIA/stroke                  5 (4.5)                  43 (1.7)     0.049
  All‐cause mortality                                               
  In‐hospital                 53 (48.2)                117 (4.7)    \<0.001
  1 month                     53 (48.2)                159 (6.3)    \<0.001
  1 year                      58 (52.7)                451 (18.0)   \<0.001
  2 year                      61 (55.4)                554 (22.1)   \<0.001
  3 year                      61 (55.4)                574 (23.0)   \<0.001

CHF, chronic heart failure; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; TIA, transient ischaemic attack; VA, ventricular arrhythmia.

Data are expressed in *n* (%). All‐cause mortality includes cumulative of previous years.

The adjusted odds ratios of in‐hospital events and mortality with respect to age and gender and in addition to presence of co‐morbidities for VA are shown as differences in two groups in *Table* [5](#ehf212525-tbl-0005){ref-type="table"}. Generally, presence of VA increased the odds of occurrence of adverse events and mortality. Cardiogenic shock when adjusted for co‐morbidities showed the highest odds, escalating from around 20 to 24 times the risk. The estimated risk of developing other conditions like recurrent HF, haemodialysis, sepsis, major bleeding, and pacing increased manifold in presence of VA. Those with in‐hospital VA had higher risk for in‐hospital, 1 month, and 3 year mortality than those without VA.

###### 

Age‐adjusted and gender‐adjusted odds ratios for ventricular arrhythmia‐related in‐hospital events and mortality in heart failure patients

  Variable             Age‐adjusted and gender‐adjusted odds ratio   Age‐adjusted, gender‐adjusted, and co‐morbidities‐adjusted odds ratio
  -------------------- --------------------------------------------- -----------------------------------------------------------------------
  In‐hospital events                                                 
  Recurrent CHF        3.9 (2.6--5.8)                                4.7 (3.0--7.2)
  Dialysis             7.2 (4.4--11.8)                               10.3 (5.8--18.4)
  Shock                19.8 (13.1--30.0)                             23.7 (15.3--36.7)
  Pacing               5.1 (2.1--12.5)                               5.8 (2.3--14.8)
  CRT                  1.7 (0.7--4.3)                                1.7 (0.7--4.5)
  ICD                  1.1 (0.5--2.4)                                1.2 (0.6--2.6)
  Major bleeding       9.6 (4.5--20.6)                               9.4 (4.3--20.7)
  TIA/stroke           2.9 (1.1--7.4)                                3.2 (1.2--8.6)
  Mortality                                                          
  In‐hospital          21.2 (13.8--32.6)                             22.8 (14.5--35.9)
  1 month              15.3 (10.1--23.3)                             16.7 (10.8--25.9)
  1 year               5.8 (3.9--8.7)                                6.6 (4.3--10.1)
  2 year               5.1 (3.4--7.6)                                5.8 (3.8--8.9)
  3 year               4.9 (3.3--7.3)                                5.6 (3.7--8.5)

CHF, chronic heart failure; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; TIA, transient ischaemic attack.

Data are presented as odds ratio (95% confidence interval).

Discussion {#ehf212525-sec-0009}
==========

Development of ventricular arrhythmia in HF patients is a serious complication necessitating prompt intervention. Many studies have reported the magnitude and prognosis associated with VA in patients hospitalized with HF. [20](#ehf212525-bib-0020){ref-type="ref"}, [21](#ehf212525-bib-0021){ref-type="ref"} However, those studies were limited to PVCs and NSVT in HF and did not investigate sustained VT and VF due to high rate of mortality.[22](#ehf212525-bib-0022){ref-type="ref"} To the best of our knowledge, this is the first study that expands the knowledge base to include the incidence, associated factors, and outcomes of patients with HF complicated by sustained VT and VF in Saudi Arabia.

The present study assessed the incidence, predictors, and mortality among HF patients with in‐hospital VA using database from national HEARTS registry in Saudi Arabia. The cohort of HF patients showed 4.2% incidence of in‐hospital VA. ST elevated myocardial infarction, previous history of arrhythmia, infection, and lower systolic blood pressure were independently associated with VA at the time of presentation. Other findings include strong association of VA with development of multiple in‐hospital cardiac events and high rate of all‐cause mortality. Some of the findings specific to Saudi population include lower age of occurrence and higher 1 month mortality.

The global incidence rates of in‐hospital VA have been reported to be fairly consistent with our study. ATLAS study showed 5.5% and Worcester Heart Attack Study reported 4.7% incidence of in‐hospital VA among myocardial infarction patients.[23](#ehf212525-bib-0023){ref-type="ref"}, [24](#ehf212525-bib-0024){ref-type="ref"} On the other hand, there was a decline in out‐of‐hospital ventricular fibrillation/ventricular tachycardia in the population as in Finnish study, which showed 48% decrease from 1994 to 1999, and another study in Sweden had reported 18% reduction in incidence of VA after 17 years of follow‐up.[25](#ehf212525-bib-0025){ref-type="ref"}, [26](#ehf212525-bib-0026){ref-type="ref"} Clinical presentation at the time of admission of the VA complicated HF patients showed significant association with male gender, previous history of VT/VF, family history of cardiomyopathy, positive troponin, lower ejection fraction, higher heart rate at presentation, and triple vessel disease. HF registries from around the globe have identified older age and male gender as pivotal risk factors. To our surprise, the mean age was lower for VA complicated HF patients. Nevertheless, the mean age (61 years ± 15 SD) of the total cohort of HF patients in our registry was much lower in comparison with other registries from the American and European region (70--75 years ± 15 SD). [4](#ehf212525-bib-0004){ref-type="ref"}, [27](#ehf212525-bib-0027){ref-type="ref"} These regional differences are controlled by many factors including economic status, literacy levels, genetic and lifestyle factors, and individual patient characteristics.[4](#ehf212525-bib-0004){ref-type="ref"} However, this important finding reflects on implications like early mortality and multiple morbidity, thus necessitating urgent planning and implementation of framework of cardiac health intervention policies in Saudi Arabia. Other clinical risk factors were similar to reports from regional and global contemporary registries.[28](#ehf212525-bib-0028){ref-type="ref"}, [29](#ehf212525-bib-0029){ref-type="ref"}

With regard to in‐hospital course, adverse events during hospitalization were more frequent in the VA group, thereby exerting a direct influence on the prognosis and outcome. In addition, HF patients with VA showed significantly higher precipitating factors, which together augmented the risk of short‐term and long‐term mortality. The HEARTS registry showed higher rates of all‐cause mortality than the global trials like EVEREST and ASCEND‐HF.[16](#ehf212525-bib-0016){ref-type="ref"}, [30](#ehf212525-bib-0030){ref-type="ref"} Other studies like GRACE, EFHS, and ATLAS are in accordance to our findings.[31](#ehf212525-bib-0031){ref-type="ref"}, [32](#ehf212525-bib-0032){ref-type="ref"}, [33](#ehf212525-bib-0033){ref-type="ref"}, [34](#ehf212525-bib-0034){ref-type="ref"} Nonetheless, despite adverse outcomes associated with VA, the investigators of PROMISE study demonstrated that NSVT specifically in addition to other clinical parameters did not add more to the prediction of sudden death in moderate‐to‐severe HF patients, but early recognition and management of in‐hospital VA by prompt defibrillation improved survival outcomes.[35](#ehf212525-bib-0035){ref-type="ref"} Herlitz and his colleagues and other studies demonstrated high rates of survival to hospital discharge upon \<3 min defibrillation after collapse among in‐hospital VF patients.[36](#ehf212525-bib-0036){ref-type="ref"}, [37](#ehf212525-bib-0037){ref-type="ref"}, [38](#ehf212525-bib-0038){ref-type="ref"} Hence, our findings suggest that the exacerbating factors may prompt vigilant monitoring of the parameters enhancing early recognition and facilitating swift initiation of defibrillation leading to substantial improvement in prognosis and better outcomes.

Furthermore, although standardized, the ICD and CRT therapy vary considerably between countries. The total prevalence of implant devices among HF patients in the present study was 12% with similar use between VA and non‐VA patients. Although this figure was overtly lower compared with countries like Italy, Israel, and Czech Republic with CRT penetration rate of 31--93%, many other countries reported a prevalence range of 0--15%.[39](#ehf212525-bib-0039){ref-type="ref"} Data from the Gulf region involving seven countries also showed prevalence below 5%.[28](#ehf212525-bib-0028){ref-type="ref"} The reasons behind such regional disparities depend on several identified barriers like the type of healthcare centre, budget and finance, insufficient referrals, and lower physician awareness of guidelines. A detailed analysis of current cohort is however required to determine the cause of such low prevalence. Such underutilization may result in substandard healthcare delivery and management of HF patients raising concern. However, a larger study may be recommended involving referral hospitals and tertiary centres representative of the population to obtain unbiased results.

The study does contain certain limitations. First, the results of the study are based on data from a registry in which the enrolment of subjects is voluntary, which may impact the quality of data as being non‐representative of the general population. Second, VA in our study included only patients with sustained VT and VF, which might have different prognostic implications in the setting of HF; information on other types such as PVCs and NSVT was not documented and hence beyond the scope of our study. Finally, the pre‐hospital VA and/or sudden death were not captured in the registry, which might underestimate the incidence of VA in our population.

To summarize, smoking men aged above 55 years with previous history of arrhythmias or MI and with family history of cardiomyopathy are more likely to develop VA subsequent to HF. VA in HF was associated with higher risk of in‐hospital events, adverse outcomes, and poor survival. The clinical implications of this research include risk identification based on presence of significant risk factors and predictors of VA that may potentially lead to early recognition and prompt management to improve outcomes. With regard to research implications, we suggest linking of more registries and develop risk stratification scores specific to Saudi population.
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